IBRDC2 Polyclonal Antibody, Cy5.5 Conjugated
Applications
Predicted Reactivity
| Overview | |
| Catalog # | bs-7613R-Cy5.5-100uL |
| Product Name | IBRDC2 Polyclonal Antibody, Cy5.5 Conjugated |
| Applications |
IF(IHC-P)
IF(IHC-F)
IF(ICC)
|
| Predicted Reactivity | Human, Mouse, Rat, Dog, Cow, Sheep, Pig, Horse, Chicken, Cat, Rabbit, GuineaPig |
| Specifications | |
| Conjugation | Cy5.5 |
| Host | Rabbit |
| Source | KLH conjugated synthetic peptide derived from human IBRDC2/RING finger protein 144B |
| Clonality | Polyclonal |
| Isotype | IgG |
| Concentration | 1ug/ul |
| Purification | Purified by Protein A. |
| Storage Buffer | Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Storage Condition | Store at -20C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target | |
| Gene ID | 255488 |
| Subcellular location | Cytoplasm, Cell membrane |
| Synonyms | E3 ubiquitin protein ligase RNF144B; RING finger protein 144B; E3 ubiquitin-protein ligase RNF144B; IBR domain containing 2; IBR domain containing protein 2; IBR domain-containing protein 2; IBRDC 2; IBRDC2; p53 inducible RING finger protein; p53-inducible RING finger protein; p53RFP; PIR2; R144B_HUMAN; Ring finger 144B; RING finger protein 144B; RNF 144B; RNF144B. |
| Background | E3 ubiquitin-protein ligase which accepts ubiquitin from E2 ubiquitin-conjugating enzymes UBE2L3 and UBE2L6 in the form of a thioester and then directly transfers the ubiquitin to targeted substrates such as LCMT2, thereby promoting their degradation. Induces apoptosis via a p53/TP53-dependent but caspase-independent mechanism. However, its overexpression also produces a decrease of the ubiquitin-dependent stability of BAX, a pro-apoptotic protein, ultimately leading to protection of cell death; But, it is not an anti-apoptotic protein per se.Tissue specificity: Broadly expressed, with lowest levels in brain and thymus, and highest levels detectable in heart, ovary and testis. |
| Application Dilution | |
| IF(IHC-P) | 1:50-200 |
| IF(IHC-F) | 1:50-200 |
| IF(ICC) | 1:50-200 |
Frequently asked questions
Which applications is IBRDC2 Polyclonal Antibody, Cy5.5 Conjugated (BS-7613R-CY5-5) validated for, and at what dilution?
BS-7613R-CY5-5 is validated for IF(IHC-P) (1:50-200); IF(IHC-F) (1:50-200); IF(ICC) (1:50-200). These are recommended starting dilutions; optimal dilutions should be determined by the end user.
How should BS-7613R-CY5-5 be stored?
Store at -20C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. Storage buffer: Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.
What immunogen was used to raise IBRDC2 Polyclonal Antibody, Cy5.5 Conjugated (BS-7613R-CY5-5)?
KLH conjugated synthetic peptide derived from human IBRDC2/RING finger protein 144B
What are the excitation and emission wavelengths of the Cy5.5 conjugate (BS-7613R-CY5-5)?
Cy5.5 on BS-7613R-CY5-5: excitation / emission 675nm/694nm.